SG11201406455YA - SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT - Google Patents
SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHTInfo
- Publication number
- SG11201406455YA SG11201406455YA SG11201406455YA SG11201406455YA SG11201406455YA SG 11201406455Y A SG11201406455Y A SG 11201406455YA SG 11201406455Y A SG11201406455Y A SG 11201406455YA SG 11201406455Y A SG11201406455Y A SG 11201406455YA SG 11201406455Y A SG11201406455Y A SG 11201406455YA
- Authority
- SG
- Singapore
- Prior art keywords
- sorcs1
- overweight
- obesity
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201270191 | 2012-04-17 | ||
PCT/DK2013/050107 WO2013156031A2 (en) | 2012-04-17 | 2013-04-17 | SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201406455YA true SG11201406455YA (en) | 2014-11-27 |
Family
ID=49384162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406455YA SG11201406455YA (en) | 2012-04-17 | 2013-04-17 | SorCS1 FOR USE IN THE TREATMENT OF OBESITY AND OVERWEIGHT |
Country Status (10)
Country | Link |
---|---|
US (1) | US20150166629A1 (de) |
EP (1) | EP2874646A4 (de) |
JP (1) | JP2015514726A (de) |
CN (1) | CN104470532A (de) |
AU (1) | AU2013248727A1 (de) |
CA (1) | CA2870211A1 (de) |
HK (1) | HK1208159A1 (de) |
IL (1) | IL235066A0 (de) |
SG (1) | SG11201406455YA (de) |
WO (1) | WO2013156031A2 (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105136781B (zh) * | 2015-08-13 | 2018-03-30 | 上海交通大学医学院附属瑞金医院 | 脂肪因子grem2作为药物靶点在治疗肥胖症药物中的应用 |
EP3666281A1 (de) | 2018-12-14 | 2020-06-17 | Insusense ApS | Zusammensetzungen, die sortilin-1 enthalten |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223392A (en) * | 1988-01-25 | 1993-06-29 | Exocell, Inc. | Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore |
AT404357B (de) * | 1995-06-13 | 1998-11-25 | Immuno Ag | Prothrombin-derivate |
BR0107561A (pt) * | 2000-01-10 | 2002-11-19 | Maxygen Holdings Ltd | Polipeptìdios ou conjugados entre polipeptìdios que exibem atividade (g-csf), métodos de preparação dos mesmos e seus usos |
WO2004022719A2 (en) * | 2002-09-09 | 2004-03-18 | Wisconsin Alumni Research Foundation | Type 2 diabetes susceptibility genes |
SI2120997T1 (sl) * | 2006-12-21 | 2017-08-31 | H. Lundbeck A/S | Modulacija aktivnosti pronevrotrofinov |
EP2008666A1 (de) * | 2007-06-29 | 2008-12-31 | Institut Pasteur | Verwendung von VHH-Antikörpern zur Herstellung von Peptidvektoren zur Verabreichung einer relevanten Substanz und Anwendungen der Peptidvektoren |
US9101117B2 (en) * | 2009-06-10 | 2015-08-11 | Aarhus Universitet | SorCS1-like agent for use in the treatment of insulin resistance and diseases related thereto |
-
2013
- 2013-04-17 EP EP13777908.8A patent/EP2874646A4/de not_active Withdrawn
- 2013-04-17 WO PCT/DK2013/050107 patent/WO2013156031A2/en active Application Filing
- 2013-04-17 CA CA2870211A patent/CA2870211A1/en not_active Abandoned
- 2013-04-17 SG SG11201406455YA patent/SG11201406455YA/en unknown
- 2013-04-17 US US14/390,937 patent/US20150166629A1/en not_active Abandoned
- 2013-04-17 AU AU2013248727A patent/AU2013248727A1/en not_active Abandoned
- 2013-04-17 JP JP2015506097A patent/JP2015514726A/ja active Pending
- 2013-04-17 CN CN201380032064.3A patent/CN104470532A/zh active Pending
-
2014
- 2014-10-07 IL IL235066A patent/IL235066A0/en unknown
-
2015
- 2015-09-09 HK HK15108775.7A patent/HK1208159A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL235066A0 (en) | 2014-12-31 |
HK1208159A1 (en) | 2016-02-26 |
US20150166629A1 (en) | 2015-06-18 |
WO2013156031A2 (en) | 2013-10-24 |
CA2870211A1 (en) | 2013-10-24 |
CN104470532A (zh) | 2015-03-25 |
JP2015514726A (ja) | 2015-05-21 |
AU2013248727A1 (en) | 2014-11-06 |
EP2874646A4 (de) | 2016-07-06 |
EP2874646A2 (de) | 2015-05-27 |
WO2013156031A3 (en) | 2013-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282128A (en) | Methods for treating overweight and obesity | |
HK1216176A1 (zh) | 用於治療增殖性和自身免疫疾病的非對稱吡咯並苯並二氮雜卓二聚物 | |
IL237125A0 (en) | Use of preparations containing niclosamide and/or its derivatives for the treatment of solid tumors | |
HK1207860A1 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3- | |
HRP20181879T1 (hr) | Spojevi za liječenje pretilosti i postupci za njihovu upotrebu | |
HK1211221A1 (en) | Formulations for the treatment and prevention of obesity | |
HK1209639A1 (en) | Gpbp-1 inhibition and its therapeutic use gpbp-1 | |
ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
IL233875A (en) | Preparation and use for the treatment of anal fissures | |
LT2845598T (lt) | Preparatas, skirtas naudoti netipinės osteoporozės prevencijai ir gydymui | |
ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
EP2744786A4 (de) | Substituierte 2-imidazolidinone und 2-imidazolone und ihre verwendung bei der behandlung von krebs | |
HK1208159A1 (en) | Sorcs1 for use in the treatment of obesity and overweight sorcs1 | |
ZA201401800B (en) | Novel plant defensins and use in the treatment of proliferative diseases | |
ZA201503266B (en) | Pyidone derivatives and uses thereof in the treatment of tuberculosis | |
SI2663185T1 (sl) | Calebin A za uporabo pri zdravljenju vnetja in debelosti | |
PT2389936E (pt) | Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca | |
HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer | |
GB201117876D0 (en) | Peptides and their use in treatment |